Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. Our scientists and leadership team have a proven track record of innovation and successful drug development of therapeutic candidates from early discovery to commercial implementation. The Companyâs mission is to introduce much needed innovations to infectious disease treatment using an anti-infective product portfolio that includes four (4) clinical stage and two preclinical drug candidates. Our antimicrobial product candidates are highly differentiated from conventional antibiotics in mechanisms of action, and are being developed using clinical study designs that allow for clear demonstration of superiority over standard of care antibiotics. Source
No articles found.
Axovant is accelerating the development of innovative gene therapy products that a...
Axovant is accelerating the development of inno...
Synlogic⢠is pioneering the development of a novel class of living Synthetic Bio...
Synlogic⢠is pioneering the development of a ...
Johnson & Johnson engages in the research and development, manufacture, and sale o...
Johnson & Johnson engages in the research and d...
We are a clinical-stage biopharmaceutical company focused on the development of no...
We are a clinical-stage biopharmaceutical compa...
Marinus Pharmaceuticals, Inc. is committed to improving the lives of patients suff...
Marinus Pharmaceuticals, Inc. is committed to i...
MEI Pharma (Nasdaq: MEIP) is a San Diego-based late-stage pharmaceutical company f...
MEI Pharma (Nasdaq: MEIP) is a San Diego-based ...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
Join the National Investor Network and get the latest information with your interests in mind.